Ss. Estani et El. Segura, Treatment of Trypanosoma cruzi infection in the indeterminate phase. Experience and current guidelines in Argentina, MEDICINA, 59, 1999, pp. 166-170
An effective treatment for Trypanosoma cruzi infection has been investigate
d since the 30s. The goals of the specific treatment against T. cruzi infec
tion are, at the individual level, to eliminate the parasite, and to reduce
the probability of developing Chagas disease. At the end of the 60s and at
the beginning of the 70s, two compounds were clinically investigated in Ar
gentina: Nifurtimox and Benznidazole. After the approval by the Ministry of
Health, in 1983 the first guidelines for the treatment of T. cruzi infecti
on were proposed and approved. These guidelines recommended the treatment o
f cases in the acute phase. Due to the publication of new information in su
pport of the utility of these drugs for treating cases in the indeterminate
phase of Chagas disease, in 1997 the original guidelines were revised and
new procedures were approved. At present, the treatment is recommended for.
1) all patients undergoing the acute phase; 2) children and young people u
ndergoing the indeterminate phase; 3) adult patients undergoing the indeter
minate phase or with incipient heart lesions; 4) laboratory accidents and d
uring surgery, and 5) organ transplant recipients or donors. The general cl
inical laboratory control is needed for the intra-treatment monitoring of t
he patient. Titration of specific antibodies with monospecific antigens has
been shown to be an adequate marker of therapeutic efficacy.